JP6814162B2 - 結腸に治療剤を送達するための組成物及び方法 - Google Patents

結腸に治療剤を送達するための組成物及び方法 Download PDF

Info

Publication number
JP6814162B2
JP6814162B2 JP2017558481A JP2017558481A JP6814162B2 JP 6814162 B2 JP6814162 B2 JP 6814162B2 JP 2017558481 A JP2017558481 A JP 2017558481A JP 2017558481 A JP2017558481 A JP 2017558481A JP 6814162 B2 JP6814162 B2 JP 6814162B2
Authority
JP
Japan
Prior art keywords
enema composition
enema
composition according
phospholipid
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017558481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515511A (ja
JP2018515511A5 (enExample
Inventor
ランジート シンハ，シダールタ
ランジート シンハ，シダールタ
ラジャダス，ジャヤクマール
ハブテツィオン，アイーダ
ディー． パムナニ，ラビンダー
ディー． パムナニ，ラビンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2018515511A publication Critical patent/JP2018515511A/ja
Publication of JP2018515511A5 publication Critical patent/JP2018515511A5/ja
Application granted granted Critical
Publication of JP6814162B2 publication Critical patent/JP6814162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017558481A 2015-05-04 2016-05-04 結腸に治療剤を送達するための組成物及び方法 Active JP6814162B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156682P 2015-05-04 2015-05-04
US62/156,682 2015-05-04
PCT/US2016/030682 WO2016179227A1 (en) 2015-05-04 2016-05-04 Compositions and methods for delivering therapeutic agents into the colon

Publications (3)

Publication Number Publication Date
JP2018515511A JP2018515511A (ja) 2018-06-14
JP2018515511A5 JP2018515511A5 (enExample) 2019-06-06
JP6814162B2 true JP6814162B2 (ja) 2021-01-13

Family

ID=57218315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558481A Active JP6814162B2 (ja) 2015-05-04 2016-05-04 結腸に治療剤を送達するための組成物及び方法

Country Status (9)

Country Link
US (3) US20180140619A1 (enExample)
EP (2) EP3291818B1 (enExample)
JP (1) JP6814162B2 (enExample)
KR (1) KR20170142181A (enExample)
AU (2) AU2016257911B2 (enExample)
CA (1) CA2984111A1 (enExample)
DK (1) DK3291818T3 (enExample)
ES (1) ES2761636T3 (enExample)
WO (1) WO2016179227A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191547A1 (en) * 2014-06-09 2015-12-17 Cornell University Implantable therapeutic delivery system and methods thereof
CA2984111A1 (en) * 2015-05-04 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivering therapeutic agents into the colon
PL3870226T3 (pl) * 2018-10-24 2023-12-27 Ferring B.V. Mukoadhezyjne kompozycje farmaceutyczne kortykosteroidów
US20210361602A1 (en) * 2020-05-22 2021-11-25 Intact Therapeutics, Inc. Dosing methods for treating inflammatory bowel conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350690A (en) * 1980-10-27 1982-09-21 Cressington Investments Ltd. Steroid composition
FR2586587B1 (fr) * 1985-08-30 1987-10-23 Adir Nouveaux surfactants artificiels, leur preparation et les compositions pharmaceutiques qui les contiennent.
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
AU2007275660B2 (en) * 2006-07-19 2012-08-02 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
US20120111756A1 (en) * 2008-12-17 2012-05-10 Altheus Therapeutics, Inc. Enema formulations
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
CA2984111A1 (en) * 2015-05-04 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivering therapeutic agents into the colon

Also Published As

Publication number Publication date
DK3291818T3 (da) 2019-12-09
EP3291818A1 (en) 2018-03-14
EP3659607A1 (en) 2020-06-03
US20180140619A1 (en) 2018-05-24
KR20170142181A (ko) 2017-12-27
ES2761636T3 (es) 2020-05-20
AU2016257911B2 (en) 2021-02-18
CA2984111A1 (en) 2016-11-10
JP2018515511A (ja) 2018-06-14
US20210283148A1 (en) 2021-09-16
EP3291818B1 (en) 2019-10-30
AU2016257911A1 (en) 2017-11-09
US20210330682A1 (en) 2021-10-28
EP3291818A4 (en) 2018-12-12
AU2021203094A1 (en) 2021-06-10
WO2016179227A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
AU2021203094A1 (en) Compositions and methods for delivering therapeutic agents into the colon
JP2000505430A (ja) ニコチンの結腸送達による炎症性腸疾患の治療
JP7350372B2 (ja) 膀胱への薬剤滴下投与用の製剤および方法と、膀胱疾患の治療
EP4259093B1 (en) Material and method for treating cancer
ES2260321T3 (es) Composicion para el tratamiento de transtornos inflamatorios.
CN106255503B (zh) 用于运载抗癌药剂的组合物
Fawaz et al. Comparative in vitro–in vivo study of two quinine rectal gel formulations
KR20170057435A (ko) 궤양성 대장염의 치료용 의약 조성물
EP3331494B1 (fr) Composition destinée à vectoriser un agent anticancéreux
CA3063420A1 (en) Treatment of epithelial cysts by intracystic injection of antineoplastic particles
JP2019533716A (ja) 医薬組成物及びその使用
TWI510243B (zh) 用於治療膀胱癌的組成物及方法
Li et al. Novel strategy of combined interstitial macrophage depletion with intravenous targeted therapy to ameliorate pulmonary fibrosis
JP2021178839A (ja) 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法
WO2009146303A1 (en) Corticosteroid microvesicles for treatment of cardiovascular diseases
WO2022205986A1 (zh) 一种司维拉姆的新用途
Jackson et al. LYTIC PHAGE ATTENUATES COLITIS SEVERITY IN GNOTOBIOTIC MICE COLONIZED WITH IBD-ASSOCIATED E. COLI NRG857C
KR20250086653A (ko) 구조화된 지질 조성물
JP2025521859A (ja) 経口投与可能な医薬剤形および高シュウ酸尿症の治療方法におけるその使用
CN120857929A (zh) 用于治疗肿瘤病理和神经性疼痛的2-羟基-十八碳烯-9-顺式-酸
CN105616349B (zh) 一种具有生物粘附性的氟尿嘧啶直肠用温度敏感性乳剂及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201218

R150 Certificate of patent or registration of utility model

Ref document number: 6814162

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250